DOTMATICS
30.3.2017 09:02:08 CEST | Business Wire | Press release
Dotmatics , a leading provider of scientific informatics solutions and services, today announced Reaction Workflows (RW), a major new application within the Dotmatics 5.1 suite that lets scientists quickly and easily define and execute common cheminformatics tasks, such as library enumeration, structure normalization and compound profiling, in a graphical workflow environment.
RW, part of the integrated Dotmatics 5.1 informatics suite, allows scientists to produce an easily understandable graphical record for sharing scientific best practices and knowledge retention within an organization. Scientists can develop workflows quickly and easily using an intuitive, drag-and-drop web-based interface without programming or scripting experience.
“Reaction Workflows provides the ability for any chemist within a company to easily perform an important set of cheminformatics tasks,” said Dotmatics’ Director and Chief Scientific Officer Mike Hartshorn, Ph.D. “This application complements the enhanced user experience and increased accessibility in our 5.1 platform suite by allowing scientists to perform their own ad-hoc analysis without the need for additional resources. This removes a common and time-consuming roadblock to meeting their goals.”
Intuitive User Interface
Within RW, workflows are built from nodes that provide inputs and outputs or perform actions. Using the drag-and-drop interface, the nodes are joined together to define a data process to perform. This makes designing or modifying workflows significantly faster and less prone to error than manual development without requiring specialized technical skills.
Immediate Productivity
The application includes a variety of chemically intelligent nodes including ones to perform reaction-, scaffold-, and transform-based enumeration. Nodes for performing structure normalization, property calculation, substructure annotation and filtering are also available. Other nodes read and write chemical structures and visualize the results or send them to Dotmatics Vortex for further analysis. The ability to perform the different types of enumeration in combination with property/structure annotation and filtering means it can be used for many common medicinal chemistry use cases. Nodes come populated with external content to ensure that chemists can be immediately productive. For example:
- The reaction node provides an extensive list of pre-built chemical reactions that are commonly used in synthetic and medicinal chemistry.
- The transform node provides a set of structural changes that are performed in medicinal chemistry to alter structures. Further reactions, transforms or scaffolds can be added easily.
- The reagent node is preconfigured with common sets of chemical reagents from Dotmatics Chemselector .
Chemistry teams or individuals can add and share additional reactions and other content to these stores based on proprietary corporate knowledge.
Address Wide Variety of Tasks
Reaction Workflows is a highly flexible application where multiple cheminformatics nodes can be joined together to build workflows quickly and thoroughly. Typical use cases include reaction-based enumeration, Markush-based enumeration, virtual library-enumeration, and profiling and structure normalization for registration. The application also allows scientists to create workflows for lead hopping, filtering and profiling sets of structures by properties and substructures. It even allows for the creation of workflows that address the important but mundane task of chemistry file cleanup, which allows cheminformaticians to automate the correction of errors and inconsistencies in data and structure files, prior to their use in design.
Integrates with Dotmatics Applications
RW is integrated into the Dotmatics Suite. Browser hit lists, for example, sets of reagents, can be used as input into the reagents node. A Vortex node can be inserted into a workflow so that the results of an enumeration and an interactive selection in Vortex can provide input to the next node in the workflow.
An Introducing Dotmatics Reaction Workflows webinar will be held Thursday, April 6, 2017, from 10:30-11:30 am Eastern Time. A What’s New in Dotmatics 5. 1 webinar will be held May 9, 2017, from 10:30-11:30 am Eastern Time. Dotmatics presenters Phil Mounteney, head of application science, North America and Gianpaolo Bravi, senior scientist and one of the lead developers of RW, will provide a product overview and lead a demonstration. To register for the April 6 webinar click here . To register for the May 9 webinar click here . A video of 5.1 including Reaction Workflows is available here .
About Dotmatics:
Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and supported on Microsoft Windows, Mac OS X and Linux. For more information visit dotmatics.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005447/en/
Contact:
Dotmatics
Marla Kertzman, +1 209-852-9027
pr@dotmatics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
